Drugs and prolactin
- PMID: 18404390
- DOI: 10.1007/s11102-008-0106-6
Drugs and prolactin
Abstract
Medications commonly cause hyperprolactinemia and their use must be differentiated from pathologic causes. The most common medications to cause hyperprolactinemia are the antipsychotic agents, although some of the newer atypical antipsychotics do not do so. Other medications causing hyperprolactinemia include antidepressants, antihypertensive agents, and drugs which increase bowel motility. Often, the medication-induced hyperprolactinemia is symptomatic, causing galactorrhea, menstrual disturbance, and erectile dysfunction. In the individual patient, it is important differentiate hyperprolactinemia due to a medication from a structural lesion in the hypothalamic-pituitary area. This can be done by stopping the medication temporarily to determine if the prolactin (PRL) levels return to normal, switching to another medication in the same class which does not cause hyperprolactinemia (in consultation with the patient's physician and/or psychiatrist), or by performing an MRI or CT scan. If the hyperprolactinemia is symptomatic, management strategies include switching to an alternative medication which does not cause hyperprolactinemia, using estrogen/testosterone replacement, or cautiously adding a dopamine agonist.
Similar articles
-
Medication-induced hyperprolactinemia.Mayo Clin Proc. 2005 Aug;80(8):1050-7. doi: 10.4065/80.8.1050. Mayo Clin Proc. 2005. PMID: 16092584 Review.
-
[Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].Encephale. 2014 Feb;40(1):86-94. doi: 10.1016/j.encep.2012.03.002. Epub 2013 Aug 5. Encephale. 2014. PMID: 23928066 Review. French.
-
Management of psychotropic-induced hyperprolactinemia.Clin Pharm. 1992 Oct;11(10):851-6. Clin Pharm. 1992. PMID: 1341991 Review.
-
Hyperprolactinemia associated with psychotropics--a review.Hum Psychopharmacol. 2010 Jun-Jul;25(4):281-97. doi: 10.1002/hup.1116. Hum Psychopharmacol. 2010. PMID: 20521318 Review.
-
Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.Drugs. 2004;64(20):2291-314. doi: 10.2165/00003495-200464200-00003. Drugs. 2004. PMID: 15456328 Review.
Cited by
-
Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma.Cancers (Basel). 2022 Jul 24;14(15):3604. doi: 10.3390/cancers14153604. Cancers (Basel). 2022. PMID: 35892862 Free PMC article. Review.
-
Persistent Idiopathic Prolactin Elevation Merits Macroprolactin Estimation: A Case Report and Review of Literature.J Hum Reprod Sci. 2021 Apr-Jun;14(2):206-210. doi: 10.4103/jhrs.jhrs_168_20. Epub 2021 Jun 28. J Hum Reprod Sci. 2021. PMID: 34316240 Free PMC article.
-
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.Nat Rev Endocrinol. 2023 Dec;19(12):722-740. doi: 10.1038/s41574-023-00886-5. Epub 2023 Sep 5. Nat Rev Endocrinol. 2023. PMID: 37670148 Review.
-
Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.Gastroenterology. 2020 Apr;158(5):1433-1449.e27. doi: 10.1053/j.gastro.2019.11.279. Epub 2019 Nov 29. Gastroenterology. 2020. PMID: 31786131 Free PMC article.
-
Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?BMC Endocr Disord. 2013 Mar 21;13:12. doi: 10.1186/1472-6823-13-12. BMC Endocr Disord. 2013. PMID: 23517652 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical